Catalent: Q2 Earnings Insights

Shares of Catalent CTLT moved higher by 1.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 40.00% year over year to $0.63, which beat the estimate of $0.55.

Revenue of $910,800,000 up by 26.25% year over year, which beat the estimate of $894,580,000.

Outlook

Catalent raised FY21 net sales guidance from $3.58 billion-$3.78 billion to $3.8 billion-$3.95 billion.

How To Listen To The Conference Call

Date: Feb 02, 2021

Time: 08:15 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.catalent.com%2F&eventid=2947415&sessionid=1&key=8483343FC92EA74634636126C2AB63F8&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $120.48

Company's 52-week low was at $31.04

Price action over last quarter: Up 17.29%

Company Description

Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.